KR20220016865A9 - 항원 결합 분자, 약학 조성물, 및 방법 - Google Patents

항원 결합 분자, 약학 조성물, 및 방법

Info

Publication number
KR20220016865A9
KR20220016865A9 KR1020217040554A KR20217040554A KR20220016865A9 KR 20220016865 A9 KR20220016865 A9 KR 20220016865A9 KR 1020217040554 A KR1020217040554 A KR 1020217040554A KR 20217040554 A KR20217040554 A KR 20217040554A KR 20220016865 A9 KR20220016865 A9 KR 20220016865A9
Authority
KR
South Korea
Prior art keywords
methods
pharmaceutical compositions
antigen binding
binding molecules
molecules
Prior art date
Application number
KR1020217040554A
Other languages
English (en)
Other versions
KR20220016865A (ko
Inventor
히카루 고가
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20220016865A publication Critical patent/KR20220016865A/ko
Publication of KR20220016865A9 publication Critical patent/KR20220016865A9/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217040554A 2019-05-15 2020-05-14 항원 결합 분자, 약학 조성물, 및 방법 KR20220016865A9 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2019-092472 2019-05-15
JP2019092472 2019-05-15
JPJP-P-2019-155042 2019-08-27
JP2019155042 2019-08-27
PCT/JP2020/019177 WO2020230834A1 (en) 2019-05-15 2020-05-14 An antigen-binding molecule, a pharmaceutical composition, and a method

Publications (2)

Publication Number Publication Date
KR20220016865A KR20220016865A (ko) 2022-02-10
KR20220016865A9 true KR20220016865A9 (ko) 2022-02-21

Family

ID=73288884

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217040554A KR20220016865A9 (ko) 2019-05-15 2020-05-14 항원 결합 분자, 약학 조성물, 및 방법

Country Status (11)

Country Link
US (1) US20230002481A1 (ko)
EP (1) EP3969475A4 (ko)
JP (1) JP2022532282A (ko)
KR (1) KR20220016865A9 (ko)
CN (1) CN114096562A (ko)
AU (1) AU2020275348A1 (ko)
BR (1) BR112021021689A2 (ko)
CA (1) CA3137649A1 (ko)
IL (1) IL287920A (ko)
MX (1) MX2021013441A (ko)
WO (1) WO2020230834A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502967A (ja) 2017-11-14 2021-02-04 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
US20240092889A1 (en) * 2019-10-16 2024-03-21 Chugai Seiyaku Kabushiki Kaisha An antibody, a pharmaceutical composition, and a method
WO2022212645A1 (en) 2021-03-31 2022-10-06 Bioverativ Usa Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
NO2708559T3 (ko) * 2008-04-11 2018-08-25
WO2012151199A1 (en) * 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
WO2014186622A2 (en) 2013-05-15 2014-11-20 Annexon, Inc. Methods of treatment for guillain-barre syndrome
CA2963760A1 (en) * 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP2021502967A (ja) * 2017-11-14 2021-02-04 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
WO2019198807A1 (en) * 2018-04-13 2019-10-17 Chugai Seiyaku Kabushiki Kaisha Anti-complement component antibodies and methods of use

Also Published As

Publication number Publication date
EP3969475A1 (en) 2022-03-23
KR20220016865A (ko) 2022-02-10
MX2021013441A (es) 2021-12-10
IL287920A (en) 2022-01-01
US20230002481A1 (en) 2023-01-05
WO2020230834A8 (en) 2021-09-23
JP2022532282A (ja) 2022-07-14
BR112021021689A2 (pt) 2022-03-22
CN114096562A (zh) 2022-02-25
EP3969475A4 (en) 2023-04-26
CA3137649A1 (en) 2020-11-19
AU2020275348A1 (en) 2021-12-09
WO2020230834A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
DK3476399T3 (da) Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf
HK1247213A1 (zh) Pd-l1抗體、其抗原結合片段及其醫藥用途
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
DK3882275T3 (da) Bifunktionelt anti-pd-1- og anti-vegfa-antistof, farmaceutisk sammensætning deraf og anvendelse deraf
IL262396B1 (en) New b7-h3 binding molecules, drug-antibody conjugates and their uses
CU20170169A7 (es) Anticuerpos de factor xi
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
BR112018010891A2 (pt) anticorpos e fragmentos de anticorpos para a conjugação específica do sítio
DK3645571T3 (da) Her3-antigen-bindende molekyler
DK3337824T3 (da) Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf
DK3356413T3 (da) Anti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf
DK3645570T3 (da) VISTA-antigenbindende molekyler
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
BR112016030183A2 (pt) anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
IL280002A (en) Antibody molecules that bind CD137 and OX40
DK3362477T3 (da) Antigenbindingsproteiner, der aktiverer leptinreceptoren
KR20220016865A9 (ko) 항원 결합 분자, 약학 조성물, 및 방법
DK3380122T3 (da) Anti-5t4 antistoffer og antistoflægemiddel konjugater
DK3269735T3 (da) Antistof mod sclerostin, antigenbindende fragment og medicinsk anvendelse deraf
SG11202101435XA (en) ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF
DK3426680T3 (da) Aktivin type 2 receptor bindende proteiner og anvendelser deraf
MA48777A (fr) Nouvelles protéines de liaison à un antigène
EP3476864A4 (en) ANTIBODIES AGAINST ETAR, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3599250A4 (en) ANTIBODY CONJUGATE, ASSOCIATED PHARMACEUTICAL COMPOSITION AND APPLICATION

Legal Events

Date Code Title Description
G170 Re-publication after modification of scope of protection [patent]
A201 Request for examination